Skyscape Web Viewer : Pharmacy Practice and the Law : Main Index

View All
radiopharmaceuticals
Farr (1989) Approved Drugs for Off-Label (Unlabeled) Indications Ramon v. Farr
reasonable safeguards
rebates
recalls
recordkeeping
red flags
red yeast rice
refill reminder exception
refills authorization of authorization of dispensing of prescriptions long-term care facilities multiple refills written on same day schedule III, IV, and V substances
registration, CSA applications for denial, revocation, or suspension dispensing distribution exemptions manufacturing modification, transfer, or termination research with controlled substance separate registrations
registration number, DEA
regulation approaches for outcomes of managed care plan formularies of prescription drug samples reasons for State Regulation of Third-Party Plans
reimbursement for drugs
reimportation of drugs
See risk evaluation and mitigation strategies (REMS) Bibliography Drug Price Competition and Patent Term Restoration Act of 1984 Food and Drug Administration Amendments Act of 2007 Historical Overview of the Federal Food, Drug, and Cosmetic Act New Drug Approval Preface Prescription Drug Labeling Information for the Patient Purpose of a Controlled Substance Prescription See risk evaluation and mitigation strategies (REMS) The Road to an Approved New Drug Application Useful Written Patient Information and Medication Guides
Renacidin
repackaging drugs adulteration regulations Food, Drug, and Cosmetic Act offenses manufacturing, defined
reregistration, applications for
research, with controlled substance
Res ipsa loquitur
Restatement (Second) of Torts, Section 402A
retail community pharmacy
retail pharmacy
retrospective review, drug use review
reverse payment agreements
Riegel v. Medtronic, Inc. (2008)
Riff v. Morgan Pharmacy (1986)
right-to-try laws
risk evaluation and mitigation strategies (REMS) Drug Information Website for Consumers and Health Professionals: Drugs@FDA FDA Safety and Innovation Act of 2012 The Road to an Approved New Drug Application